ALK and non-small cell lung carcinoma: Additionally, a subgroup analysis also demonstrated that our combination is more effective for nonsmokers than for former smokers, similar to that found with anlotinib plus pemetrexed in EGFR/ALK wild‐type advanced nsq‐NSCLC [33].